Description

Co-Amlessa (perindopril tert-butylamine, indapamide, amlodipine) tablets 8 mg/2.5 mg/5 mg. №30

Ingredients:

Each tablet contains:

• Perindopril tert-butylamine 8 mg
• Indapamide 2.5 mg
• Amlodipine 5 mg

Dosage:

The recommended dose is one tablet daily, preferably taken in the morning with or without food.

Indications:

Co-Amlessa tablets are indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy.

Contraindications:

Do not use Co-Amlessa if you are allergic to any of the ingredients, have a history of angioedema related to previous ACE inhibitor therapy, or if you are pregnant.

Directions:

Swallow the tablet whole with a glass of water. Do not crush or chew the tablet.

Scientific Evidence:

Studies have shown that the combination of perindopril, indapamide, and amlodipine in Co-Amlessa tablets provides effective blood pressure control in hypertensive patients. The synergistic action of these three components targets different pathways involved in blood pressure regulation, leading to improved outcomes compared to monotherapy.

Research published in the Journal of Hypertension demonstrated that the triple combination therapy of perindopril, indapamide, and amlodipine resulted in a greater reduction in systolic and diastolic blood pressure compared to dual combinations or monotherapy. This highlights the superior efficacy of Co-Amlessa in managing hypertension.

Additional Information:

It is important to regularly monitor blood pressure levels while taking Co-Amlessa tablets to ensure optimal control. In case of any adverse reactions or concerns, consult a healthcare professional immediately. Avoid sudden discontinuation of the medication as it may lead to a rebound increase in blood pressure.

Patients with liver or kidney impairment should use Co-Amlessa with caution and under medical supervision. The combination of perindopril, indapamide, and amlodipine may require dosage adjustments in such individuals to prevent potential complications.